-
In the battle against breast cancer as much as 35% of the patients does not respond to tamoxifen, an FDA approved drug for the treatment and prevention of breast cancer. Today researchers announced to have found the molecular on-off switch that tamoxifen uses and which prevents it from working in certain women. This information, published in the journal Nature, can predict who will respond to the
제약단신
메디칼라이터팀
2008.11.16 00:00
-
Irritable bowel syndrome (IBS), which causes patients to suffer from pain, discomfort, chronic or recurrent constipation, or diarrhea -- or bouts of both, can best be treated with older drugs like fiber antispasmodics (buscopan) and peppermint oil. After reviewing trials that included more than 2,5 thousand patients, comparing the above mentioned drugs to a placebo or no treatment, researchers fou
제약단신
메디칼라이터팀
2008.11.14 00:00
-
US Federal health officials said they will use a new early warning system for fast-spreading flu outbreaks. This system will track when and where Americans enter keywords like flu symptoms into Google and show a chart of changes in flu activity around the country. In this way (http://www.google.org/flutrends/) regional outbreaks of the flu will be detected a week to 10 days earlier than before
제약단신
메디칼라이터팀
2008.11.14 00:00
-
Heart attack and heart failure patients have a higher risk of a second heart attack or death if they take certain painkillers according to a study in Denmark. The analysis of more than 58 thousand MI patient records and more than 100 thousand heart failure patient records showed that the risk doubled within the first 90 days after use of Celebrex or the withdrawn Vioxx (rofecoxib) compared with th
제약단신
메디칼라이터팀
2008.11.14 00:00
-
Aprovel (irbesartan) marketed by Sanofi-Aventis failed in a large study, that lasted more than 4 years, presented at the AHA"s scientific meeting and also published online by the N Engl J Med, to show a benefit among patients with a common and difficult-to-treat form of heart failure. Among the 4,128 study participants hardly any difference was found in deaths or hospital admissions, when compari
제약단신
메디칼라이터팀
2008.11.14 00:00
-
A new study, presented at the AHA annual scientific meeting, found that the risks for heart stent patients taking the anti-clotting drug Plavix (clopidogrel) increased if they also took anti-ulcer medicines. Reviewing more than 14,000 medical records from 2005 to 2006 showed that in patients who had not suffered a previous heart attack, 32.5 percent who used both drugs experienced an MI or stroke
제약단신
메디칼라이터팀
2008.11.14 00:00
-
The Exubera factory, in which the company invested over three hundred million dollar during the last 10 years, remained useless after Exubera, an inhaled insulin didn’t meet the expectations and was taken of the market.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
The 6 months results from the READ 2 study, which compares the effects of intravitreal ranibizumab (Lucentis, Genentech) 0.5 mg with focal laser treatment, suggest a benefit for ranibizumab in the treatment of diabetic macular edema (DME). At the same time the twelfth-month results from the RESOLVE phase 2 trial, comparing ranibizumab with placebo in 151 patients, indicate likewise.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
The British Medicines and Healthcare products Regulatory Agency (MHRA) has issued an update relating the smoking-cessation drug Chantix (varenicline) to depression and suicide saying that some 3,541 reports of suspected adverse reactions have been received. Previously the FDA issued a similar warning.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
Earlier this year, the FDA issued a warning that osteoporosis drugs can cause severe muscle, bone, or joint pain. Recent research has discovered that such medications may cause atrial fibrillation. Doctors should prescribe them with caution to those patients who can tolerate them.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
An analysis of 33 studies on beta blockers has concluded that they are not useful in any surgical procedure other than heart surgery. Instead, the use of beta blockers in most surgeries may actually increase the risk of stroke and bradycardia. At the moment the guidelines of both ACC and AHA recommend beta blockers in order to prevent surgical complications in non coronary operations.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
A California appeals court ruled that the duty of name-brand prescription drug manufacturers extends not only to consumers of its own product, but also to those patients whose doctors predictably rely on the name-brand manufacturer"s product information when prescribing a medication.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
The FDA questions whether Remoxy (oxycodone), a proposed pain pill in controlled-release form is tamper-resistant, because of short test times the drug was studied. Control-release pills are often crushed by abusers in order to get the complete dose at once.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
Johnson & Johnson-Merck Consumer Pharmaceuticals are recalling certain bottles of nonstaining Mylicon gas-relief drops, sold in one-ounce plastic bottles with the numbers SMF007 and SMF008 printed on the lower-left side of the sticker, because some bottles may contain metal fragments.
제약단신
메디칼라이터팀
2008.11.13 00:00
-
RNA interference seems to have the ability to cancel out disease-causing genes. Dangerous levels of cholesterol in patients have been tracked down to be caused by different gene characteristics. In those patients the approach of RNA interference can silence the troubling gene, instead of attacking the cholesterol levels it produced. At the moment there are at least six RNA drugs being tested in pe
제약단신
메디칼라이터팀
2008.11.13 00:00
-
The recent Crestor (rosuvastatin) study results provide powerful evidence that lives can be saved by lowering blood cholesterol in persons with high blood levels of C-reactive protein (CRP). The study however included patients with other risk factors, like obesity and smoking, which may have influenced the study outcome. The link between high CRP levels and heart disease has been suggested before
제약단신
메디칼라이터팀
2008.11.13 00:00
-
The Food and Drug Administration (FDA) has a new webpage intended to provide one-stop shopping for post market drug safety information. The website provides links to an array of data, including information on drug labels, medications that have risk evaluation, mitigation strategies, etc
제약단신
메디칼라이터팀
2008.11.12 00:00
-
Merck & Co. has eight heart drugs in human testing, almost a fifth of all its late-stage projects. The company is experimenting with drugs to reduce blood vessel inflammation, blood pressure medicines with fewer side effects and treatment to increase so-called good cholesterol. The company wants to buy or collaborate with companies with promising cardiac treatments.
제약단신
메디칼라이터팀
2008.11.12 00:00
-
Pfizer, Merck and Sanofi-Aventis suffered recently setbacks in the development of anti-obesity drugs, abandoning further development of cannabinoid receptor antagonists. But the potential reward from treating the world"s fat epidemic is luring so the quest will continue. Two other drugs are currently being tested: orlistat curbs the absorption of fat in the intestine by blocking a pancreatic enzy
제약단신
메디칼라이터팀
2008.11.12 00:00
-
A vaccine based on priming "killer" T-cells, the heavy artillery of the immune system, succeeds in tackling the SIV, a close relative to HIV, in lab animals. The monkeys were able to intercept the replication of the virus and remained healthy for more than 500 days after infection.
제약단신
메디칼라이터팀
2008.11.12 00:00